Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Thursday

by · The Cerbat Gem

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $78.3340 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.15. The firm had revenue of $82.39 million for the quarter, compared to analysts’ expectations of $62.55 million. On average, analysts expect Esperion Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Trading Down 5.6%

Shares of NASDAQ:ESPR opened at $2.87 on Thursday. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.94. The business has a fifty day simple moving average of $2.62 and a 200 day simple moving average of $1.68. The firm has a market cap of $578.65 million, a price-to-earnings ratio of -5.86 and a beta of 0.96.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ESPR shares. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, September 19th. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, September 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Esperion Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Check Out Our Latest Stock Report on Esperion Therapeutics

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP raised its holdings in Esperion Therapeutics by 46.2% during the second quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock valued at $5,206,000 after buying an additional 1,679,294 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Esperion Therapeutics by 3.1% in the second quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock worth $4,513,000 after purchasing an additional 137,691 shares during the period. Invesco Ltd. increased its stake in shares of Esperion Therapeutics by 93.3% in the second quarter. Invesco Ltd. now owns 493,929 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 238,449 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of Esperion Therapeutics by 238.3% in the second quarter. Qube Research & Technologies Ltd now owns 485,603 shares of the biopharmaceutical company’s stock worth $478,000 after purchasing an additional 342,067 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Esperion Therapeutics by 16.8% in the second quarter. Rhumbline Advisers now owns 275,688 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 39,658 shares during the period. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Further Reading